



STUDY ON ECONOMIC VALUE AND COST EFFECTIVENESS OF PHYSICAL ACTIVITY CANCER- PREVENTIVE MEASURES

DELIVERABLE 4.6

CONTRIBUTION TO WP4 – IMPLEMENTATION AND
EVALUATION OF PILOT PROGRAMME

University of Seville



Co-funded by
the European Union



Authors:

- María de la Casa Almeida, University of Seville.
- María Jesús Casuso Holgado, University of Seville.
- Esther María Medrano Sánchez, University of Seville.
- Carmen María Suárez Serrano, University of Seville.
- Luis Andrés Zambrana, University of Seville.



With the Support of:

- Foundation of the Europe Region of World Physiotherapy (ERWP)

DISCLAIMER

The European Commission support for the production of this publication does not constitute the endorsement of the content, which reflects only the authors views. The Commission cannot be held responsible for any use which may be made of the information contained therein.

INDEX

Abbreviations	4
Summary	5
1. Introduction	6
2. Methods	8
2.1 Data sources and search strategy	8
2.2 Eligibility criteria	10
2.3 Study selection	11
2.4 Data extraction and data synthesis	12
3. Results	12
3.1 Study selection	12
3.2 Participants' characteristics description	14
3.3 Exercise interventions and comparators description	14
3.4 Results of the exercise interventions on clinical outcomes: effectiveness	15
3.5 Economic analysis description	26
3.6 Results of economic evaluations: cost-effectiveness	31
4. Conclusions	36
References	37
Supplementary material	47

Abbreviations

CEA: Cost-effectiveness analysis

CUA: Cost-utility analysis

CRF: Cancer-Related Fatigue questionnaire

DASH: Disabilities of the Arm, Shoulder, and Hand

EORTC: European Organisation for Research and Treatment of Cancer

EORTC-QLQ-BR23: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Function and Symptoms scales

EORTC-CR29: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Colorectal Cancer module

EORTC-QLQ-C30: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire

EORTC-QLQ-PR25: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Prostate Cancer

EQ-5D: European Quality of Life-5 Dimensions

FAACT-B+4-MS: Functional Assessment of Cancer Therapy-Breast

ICERs: Incremental cost-effectiveness ratios

NNT: Number Needed to Treat

PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses

QALYs: Incremental quality-adjusted life-years

RCTs: Randomised controlled trials

RR: Relative risk

SF-12: 12-Item Short-Form Health Survey

SF-36: 36-Item Short-Form Health Survey

WTP: willingness-to-pay

WHO: World Health Organization

Summary

Introduction. Scientific evidence supports the effectiveness of exercise and physical activity in the prevention and treatment of various types of cancer, as well as in improving patient survival and quality of life. However, although there are indications that exercise interventions may be cost-effective, the evidence remains limited. Therefore, the purpose of this report was to systematically review current evidence on the cost-effectiveness of exercise therapy in cancer population.

Methods. A systematic review of economic evaluations performed alongside randomised controlled trials (RCTs) was developed. An electronic search was conducted in five databases and study selection and data extraction was independently performed by two reviewers. Differences in costs and incremental cost-effectiveness ratios (ICERs) were descriptively analysed.

Results. A total of 653 records were identified from the databases, of which 10 reports (9 RCTs) recruiting 2,344 participants (mean age 56.2 years, 87% female) were finally included. Breast cancer was the most commonly studied cancer, followed by colorectal cancer and prostate cancer.

Conclusions. Evidence suggests that the cost-effectiveness of exercise therapy in cancer population may be variable, depending on factors such as the type of cancer, the timing of the intervention and the extent of the costs considered. The heterogeneity observed in the different economic studies makes it difficult to draw general conclusions and to directly compare the findings reported in different studies. Future economic evaluations on this topic should be desirable, as they can provide valuable insights and inform policy decisions.

1. Introduction

Physical activity is known to benefit a range of health outcomes in adults, improving all-cause mortality, mental and cognitive health and sleep, symptoms of anxiety and depression, and obesity (WHO, 2020). Specifically in cancer prevention, we know that between 30% and 50% of cancer deaths could be prevented by modifying or avoiding key risk factors and implementing existing evidence-based prevention strategies (WHO, 2020).

There is strong epidemiological evidence that being physically active reduces the risk of several types of cancer, including bladder (Rodríguez-Cintas et al., 2021; Keimling et al., 2014), breast (Gonçalves et al., 2014; Hardefeldt et al., 2017; Namiranian et al., 2014; Neil-Sztramko et al., 2017; Pizot et al., 2016; Poorolajal et al., 2021), colon (Puzzono et al., 2021; Shaw et al., 2018), endometrium (Schmid et al., 2015), kidney (Al-Bayati et al., 2018; Behrens et al., 2013; Williams et al., 2014), oesophagus and stomach (Behrens et al., 2014; Psaltopoulou et al., 2016; Poorolajal et al., 2020).

In contrast, higher levels of physical inactivity are associated with poor health outcomes in older adults (WHO, 2020), and sedentary behaviour is known to be associated with an increased risk of different types of cancer (Wild et al., 2020; National Cancer Institute, 2020). A recent umbrella review comprising 77 original studies concluded that high sedentary behaviour levels increase the relative risk (RR) for developing ovarian (RR: 1.29), endometrial (RR: 1.29), colon (RR: 1.25), breast (RR: 1.08), prostate (RR: 1.08), and rectal cancers (RR: 1.07). In addition, the same study also reported an increased risk of cancer mortality of 1.18 (95% CI = 1.09-1.26) (Hermelink et al., 2022).

Beyond cancer prevention, there is strong evidence of the role of physical activity to manage some cancer side effects, such as anxiety, depressive symptoms, fatigue, health related quality of life, lymphoedema and physical function (Campbell et al., 2019; Gupta et al., 2025). In addition, several studies have highlighted the protective effect of physical activity and exercise on both cancer recurrence and mortality in cancer survivors (McTiernan et al., 2019; Bui et al.,

2025; Cormie et al.; 2017, Dong et al., 2025; Gunnell et al., 2017; Perrier et al., 2025).

Cost-Effectiveness and Cost-Utility of Exercise in Cancer Prevention and Treatment

The concepts of cost-effectiveness and cost-utility are essential for evaluating the economic feasibility of exercise interventions in the oncology setting. Cost-effectiveness assesses the cost of an intervention in relation to its clinical effectiveness, whereas cost-utility incorporates quality-adjusted life years (QALYs) as an outcome measure.

A systematic review of cost-effectiveness studies on physical activity interventions in cancer survivors from high-income countries found that some interventions were cost-effective; however, the results varied depending on the intensity of the activity and the clinical context (Gubler-Gut et al. 2021).

As we have seen, scientific evidence supports the effectiveness of exercise and physical activity in the prevention and treatment of various types of cancer, as well as in improving patient survival and quality of life. However, although there are indications that exercise interventions may be cost-effective, the evidence remains limited, and further research is needed to accurately determine the cost-benefit of these interventions across different cancer types.

Therefore, the purpose of this report was to systematically review current evidence on the cost-effectiveness of exercise therapy in cancer population.

2. Methods

To provide the most robust synthesis of the evidence on the cost-effectiveness of exercise-based interventions in the cancer population, this report has been developed in accordance with the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (Page et al., 2020).

2.1 Data sources and search strategy

The search was conducted in PubMed, Embase, PsycInfo, CINHALL and SPORTDiscus databases from their inception to November 2024. Among others, Medical Subjects Heading (MeSH) terms as “exercise”, “training” or cancer were used, adapting the search strategy to the different databases requirements. The full search strategy for each database is reported in **Table 1**.

Table 1. Search strategies.

PUBMED	(("cost analy*" [Title/Abstract] OR "cost benefit*" [Title/Abstract] OR "cost utilit*" [Title/Abstract] OR "cost-minimization" [Title/Abstract] OR "cost-effectiveness" [Title/Abstract] OR "cost-effective" [Title/Abstract] OR "cost efficien*" [Title/Abstract] OR "economic evaluation" [Title/Abstract] OR "economic analy*" [Title/Abstract] OR "health-economic" [Title/Abstract] OR "value of money" [Title/Abstract]) AND ("exercise" [Title/Abstract] OR "physical activity" [Title/Abstract] OR "training" [Title/Abstract]) AND ("cancer" [Title/Abstract] OR "oncology" [Title/Abstract] OR "palliative" [Title/Abstract] OR "metasta*" [Title/Abstract])) AND ((randomizedcontrolledtrial[Filter] AND (humans[Filter]))
EMBASE	('cost analy*':ti,ab,kw OR 'cost benefit*':ti,ab,kw OR 'cost utilit*':ti,ab,kw OR 'cost minimization':ti,ab,kw OR 'cost effectiveness':ti,ab,kw OR 'cost effective':ti,ab,kw OR 'cost efficien*':ti,ab,kw OR 'economic evaluation':ti,ab,kw OR 'economic analy*':ti,ab,kw OR 'health economic':ti,ab,kw OR 'value for money':ti,ab,kw) AND (exercise:ti,ab,kw OR 'physical activity':ti,ab,kw OR training:ti,ab,kw) AND (cancer:ti,ab,kw OR oncology:ti,ab,kw OR palliative:ti,ab,kw OR metasta*':ti,ab,kw) AND 'human'/de AND 'randomized controlled trial'/de
CINHAL	AB (cost analy* OR cost benefit* OR cost utilit* OR cost minimization OR cost effectiveness OR cost effective OR cost efficien* OR economic evaluation OR economic analy* OR health economic OR value for money) AND AB (exercise OR physical activity OR training) AND AB (cancer OR oncology OR palliative OR metasta*) AND AB random*
SPORTDISCUS	AB (cost analy* OR cost benefit* OR cost utilit* OR cost minimization OR cost effectiveness OR cost effective OR cost efficien* OR economic evaluation OR economic analy* OR health economic OR value for money) AND AB (exercise OR physical activity OR training) AND AB (cancer OR oncology OR palliative OR metasta*) AND AB random*
PSYCINFO	abstract(cost analy* OR cost benefit* OR cost utilit* OR cost minimization OR cost effectiveness OR cost effective OR cost efficien* OR economic evaluation OR economic analy* OR health economic OR value for money) AND abstract(exercise OR physical activity OR training) AND abstract(cancer OR oncology OR palliative OR metasta*) AND abstract(random*)

2.2 Eligibility criteria

We defined our eligibility criteria (**Table 2**) following the accepted PICOS framework for literature search (P: Population, I: Intervention, C: Comparison, O: Outcomes, S: Study Design) as follows (Eriksen & Frandsen, 2018):

Inclusion criteria:

(P): People over 18 years old with any type of cancer diagnosis (stages I-IV). They can be undergoing primary adjuvant treatments (e.g. chemotherapy or radiation therapy) or have finalized them (survivorship phase) (Khan et al., 2012).

(I): Any type of physical exercise (e.g., endurance/aerobic, resistance/strengthening, stretching, coordination) as defined by the World Health Organization (WHO): *A subcategory of physical activity that is planned, structured, repetitive, and purposeful in the sense that the improvement or maintenance of one or more components of physical fitness is the objective* (Bull et al., 2020).

For inclusion, a clear exercise prescription based on duration, frequency, and/or intensity had to be set. Moreover, physical exercise should be applied as a single intervention.

(C): Any intervention other than physical exercise or absence of intervention.

(O): Costs and/or incremental cost-effectiveness ratios (ICERs).

(S): Economic evaluations performed alongside randomised controlled trials (RCTs) that conducted a cost analysis, cost-effectiveness and/or cost-utility analysis.

The exclusion criteria were: RCTs involving prehabilitation exercises or multimodal interventions that combine exercise programs with other non-exercise

interventions. RCTs based on general exercise recommendations were also excluded. There were no language or publication date restrictions.

Table 2. Study selection criteria.

Inclusion criteria	Exclusion criteria
Randomised controlled trials including: - Adults with a diagnosis of any type of cancer in treatment or survivors - Any type of physical exercise intervention as defined by the WHO and apply as a single therapy - Any intervention other than exercise or no intervention as comparator - Costs and/or incremental cost-effectiveness ratios (ICERs) as economic evaluation outcomes	Randomised controlled trials including: - Prehabilitation exercises or multimodal interventions (exercise plus another therapy) - General exercise recommendations without clear prescription parameters

2.3 Study selection

Two reviewers independently performed the study selection process. They first removed duplicates using Mendeley desktop citation management software (v1.19.8) and screened titles and abstracts of all records using the PICOS eligibility criteria mentioned above. The full texts were then assessed. Disagreements between reviewers were resolved by discussion (6 studies) and, if necessary, a third reviewer was consulted (2 studies).

2.4 Data extraction and data synthesis

Data were extracted from each study by two independent reviewers. A customised data extraction sheet was used to collect the following data: bibliometric data (ie, first author, year of publication, country, related RCT), characteristics of participants (i.e., cancer site, under treatment/survivor, sample size by groups and mean age), intervention details (i.e., exercise modality, duration, frequency, intensity), type of control group, health outcomes and points of assessment), economic evaluation (i.e., type of analysis, outcome indicator, time horizon and analysis perspective) and main findings. This information was synthesised and displayed in tables of studies characteristics. Finally, costs and incremental cost ratios were synthesised descriptively.

3. Results

3.1 Study selection

A total of 653 records from databases were identified of which 24 were full-text retrieved. Finally, 10 reports (9 RCTs) were included (**Figure 1**). **Table S1** contains a full list of the records excluded in the last step (n= 14) and reasons.

The two studies by Gordon et al. (2017 and 2020) originate from the same clinical trial (Hayes et al., 2013). Therefore, they are considered as a single study in the clinical synthesis (n= 9), but are considered separately in the economic synthesis (n=10) as they focus on different time horizons.




Figure 1. PRISMA 2020 flow diagram.

3.2 Participants' characteristics description

In the nine selected randomised clinical trials, a total of 2,344 participants were included ($n = 1,382$ in the experimental group and $n = 962$ in the control group). Concerning sample characteristics, the mean age was 56.2 years, and 87% were women ($n = 2,036$), most of whom were diagnosed with breast cancer ($n = 1,978$), although 22 had colorectal cancer and 40 had multiple myeloma. Among the male participants ($n = 308$), 2 had breast cancer, 202 had prostate cancer, 55 had colorectal cancer, and 67 had multiple myeloma or lymphoma.

3.3 Exercise interventions and comparators description

Most of the analysed studies implemented interventions combining aerobic exercise (e.g., walking, running, or cycling) with resistance training. Exceptions include Mewes et al. (2015), which applied aerobic training only, and Ax et al. (2022), which included two experimental groups - one receiving both aerobic and resistance training, and the other receiving aerobic training alone.

The duration of the interventions varied, ranging from 12 weeks (Mewes et al., 2015) to 9 months (Schoute et al., 2025). Ax et al. (2022) was the only study to conduct an 18-month follow-up, while both Haines et al. (2010) and Bruce et al. (2021) included a 12-month follow-up.

Although programme structures varied across studies, most included sessions of approximately 60 minutes. Depending on session frequency, the total weekly training volume ranged from 120 minutes (Edmunds et al., 2020; Schoute et al., 2025; van Dongen et al., 2019), to 150 minutes (Ax et al., 2022; Mewes et al., 2015), and up to 180 minutes per week in Gordon et al. (2017, 2020) and May et al. (2017). Regarding supervision, only a subset of these studies incorporated professional oversight (Ax et al., 2022; Bruce et al., 2021; Edmunds et al., 2020; May et al., 2017; Schoute et al., 2025; van Dongen et al., 2019).

In terms of training intensity, volume, dosage, and progression, there was considerable variability across studies. For instance, Ax et al. (2022) compared two experimental groups: one underwent progressive resistance training increasing from 6 to 10 RM, while the other trained only up to 50% of 10 RM. Similarly, Edmunds et al. (2020) implemented resistance training with 2 to 4 sets of 12 repetitions at 6 RM, while aerobic training targeted 70–85% of maximum heart rate, corresponding to 11–13 points on the Borg Rating of Perceived Exertion Scale (6–20 scale).

In contrast, Gordon et al. (2017, 2020) adjusted exercise progression based on individual participant capacity, as did Schoute et al. (2025), May et al. (2017), Mewes et al. (2015), and van Dongen et al. (2019). Other studies, such as Bruce et al. (2021) and Schoute et al. (2025), reported greater exercise intensity among participants who adhered to the intervention compared to those in the control group.

3.4 Results of the exercise interventions on clinical outcomes: effectiveness

Although this review focuses on the economic impact of exercise therapy for cancer, it also presents a synthesis of the clinical results of the primary RCTs on which the economic evaluations are based. The focus on clinical variables required a search for the original clinical trials that included all measured variables. These are larger clinical trials such as Phys-Can (Demmelmair et al, 2021), the PACT study (Travier N et al., 2015), the EFFECT study (Hiensch AE et al., 2024), the EfH trial (Hayes et al., 2013) or the EXIST study (Persoon S et al., 2017), which were consulted to obtain the results and clinical effectiveness of the intervention in patients with various types of cancer (**Table 3**).

Table 3. Original RCTs from which clinical data have been extracted.

Economic report	Primary RCT
Ax et al., 2022	Demmelmaier et al., 2021. PhysCan Project
Edmunds et al., 2020	Galvão et al., 2014. RADAR trial
Gordon et al., 2017, 2020	Hayes et al., 2013. EfH trial
May et al., 2017	Travier et al., 2015. PACT trial
	Van Vulpen et al., 2016 PACT trial
Mewes et al., 2015	Duijts et al., 2012
Schouten et al., 2025	Hiensch et al., 2022. PREFERABLE EFFECT trial
van Dongen et al., 2019	Persoon et al., 2017. EXIST trial

3.4.1. Quality of Life

The variable consistently assessed across all the analysed studies was quality of life. Later, in the cost-effectiveness analysis, we will examine the usefulness of this measure in determining to what extent the cost of the intervention translates into improvements in quality of life. However, data were also obtained regarding the clinical effectiveness of the intervention in the experimental groups in terms of quality of life.

Of the nine studies included in this analysis, eight utilised quality of life scales such as the SF-36, EORTC, or EQ-5D-3L, with the exception of the study by Gordon et al. (2017,2020), which employed the FACT-B-4 scale.

The results following the experimental interventions were heterogeneous; however, most studies (Bruce et al., 2021; Edmunds et al., 2020; Gordon et al., 2017; Gordon et al., 2020; Haines et al., 2010; Mewes et al., 2015; Schouten et al., 2025) reported improvements in patients' quality of life. Only the studies by Ax et al. (2022) and van Dongen et al. (2019) did not demonstrate a measurable improvement in this outcome (**Table 4**).

3.4.2. Fatigue

In the six studies that measured this variable (Ax et al., 2022; Gordon et al., 2017; Gordon et al., 2020; Haines et al., 2010; May et al., 2015; Schouten et al., 2025; van Dongen et al., 2019), we found a predominant use of the Cancer Related Fatigue questionnaire (CRF) for data collection (Ax et al., 2020; Haines et al., 2010; May et al., 2015; van Dongen et al., 2019). Other studies used the Functional Assessment of Chronic Illness Therapy—Fatigue (FACIT-F) scale (Gordon et al., 2017), the eFACIT-F questionnaire, the Fatigue Quality List (May et al., 2015), and the EORTC Cancer-related Fatigue QLQ-FA12 (Schouten et al., 2025).

Data on cancer-related fatigue show differing results across studies. Four of them show significantly lower levels of physical fatigue in the intervention group compared to the control group, with the Ax et al. (2022) study highlighting improvements favoring the high-intensity exercise group compared to the low-moderate-intensity group. In contrast, Haines et al. (2015) and van Dongen et al. (2019) respective studies found no significant differences in fatigue levels between the comparison groups (**Table 4**).

3.4.3. Lymphoedema

The occurrence of limb oedema was analysed in two of the studies included in this review (Bruce et al., 2021; Haines et al., 2010). Circumferential measurements or simple clinical observation were used as assessment tools. Any study found significant differences between baseline measurements and those taken after the intervention (**Table 4**).

3.4.4. Upper limb functionality

Of the nine studies included, only two collected data on participants' upper limb function (Bruce et al., 2017; Gordon et al., 2017,2020). Both used the same measurement instrument: the DASH questionnaire.

The results of the two studies are completely opposite. While Bruce et al. (2017) obtained statistically and clinically significant data in favour of the intervention group, the study by Gordon et al. (2017, 2020) did not obtain significant differences between the study groups (**Table 4**).

3.4.5. Physical Function: Physical/cardiorespiratory capacity

General physical and cardiorespiratory capacity was assessed in four studies using various measurement tools. These included the modified Balke protocol (Ax et al., 2022), the 3-minute step test (Gordon et al., 2017; Gordon et al., 2020), the 6-minute walk test (Haines et al., 2010), and the 400-meter walk test along with the chair rise test (Edmunds et al., 2020). Only the study by Edmunds et al. (2020) reported significant differences between baseline and post-intervention measurements in the tests employed (**Table 4**).

3.4.6. Pain: postoperative and neuropathic

Of the studies included in this review, only four collected data on pain, either as postoperative pain (Bruce et al., 2021), as neuropathic pain (Bruce et al., 2021; Gordon et al., 2017; Gordon et al., 2020), or as a dimension of quality of life (May et al., 2017; Schouten et al., 2024).

Regarding postoperative pain, Bruce's study showed that pain intensity improved at 12 months in the intervention group compared to usual care.

Regarding neuropathic pain, both Bruce et al. (2021), and Gordon et al. (2017,2020) showed no differences between the groups. The data collected on pain as a dimension of quality of life, using the EORTC-QLQ-C30 questionnaire, are inconsistent between the two studies. On the one hand, the primary studies of May et al. (2017) showed a negative effect size for pain, compared to Schouten et al. (2025), who presented beneficial and clinically relevant results for pain. Finally, the study by Haines et al. (2010) does not include pain as one of its outcome variables, although it does report the onset of pain as an adverse effect of exercise. Musculoskeletal pain occurred in 9 subjects in the sample, three in the control group and six in the intervention group. Of these, three reported the onset of pain while performing their programmes, two in the intervention group and one in the control group, which forced them to discontinue the activity (**Table 4**).

3.4.7. Body composition

The studies by Edmunds et al. (2020), Gordon et al. (2017,2020), and Haines et al. (2010) examined the effectiveness of the intervention in modifying body composition. Bioelectrical impedance analysis was used in the studies by Gordon et al. (2017, 2020) and Haines et al. (2010), while dual-energy X-ray absorptiometry (DEXA) was employed in the study by Edmunds et al. (2020). Notably, only the Edmunds et al. (2020) study reported a significant improvement in body composition at six months post-intervention (**Table 4**).

Keypoints on clinical outcomes measures:

- Although the experimental interventions varied across the studies included, the majority reported improvements in patients' quality of life.
- Higher-intensity exercise was associated with reduced levels of physical fatigue.
- Postoperative pain intensity showed improvement at 12 months in the intervention groups compared to usual care. However, evidence supporting the effectiveness of exercise on neuropathic pain remains insufficient, despite some beneficial and clinically meaningful outcomes being reported.
- There is not enough evidence supporting the effectiveness of the intervention in improving upper limb function, lymphoedema, body composition or general physical and cardiorespiratory capacity, although several studies showed significant differences.

Table 4. Description of the studies included based on primary RCTs.

Author(s), year Country <i>Related RCT</i>	Cancer site, sample size (mean age, SD) <i>Under treatment/survivor</i>	Type of exercise training and control condition	Clinical outcomes <i>Assessment points</i>	Main findings on clinical outcomes	Main conclusions on clinical outcomes
Ax et al., 2022 Sweden <i>Phys-Can trial</i>	Breast, colorectal, and prostate cancer (n=619) EG (n= 534): mean age 59 ($\pm$ 10) CG (n= 85): mean age 60 ($\pm$ 10) <i>Undergoing (neo) adjuvant oncological treatment</i>	High-intensity (HI) and low-to-moderate (LMI) intensity resistance and endurance exercise programme Control group: HI plus behaviour change support (BCS), LMI plus BCS	» Cancer-related fatigue » Quality of life (QoL) » Mood » Disability » Cardiorespiratory fitness » Muscle strength <i>T0: baseline; T1: 6 months</i>	There were small but significant between-group differences in physical fatigue, muscle strength and cardiorespiratory fitness in favour of HI exercise.	Patients undergoing (neo) adjuvant treatment for breast, prostate or colorectal cancer can safely exercise at HI or LMI, according to their own preferences. Additional BCS does not provide extra benefit in supervised, well-controlled exercise interventions.

Bruce et al., 2021 United Kingdom PROSPER trial	Breast cancer women with high risk of upper limb disability after surgery (n= 382) EG (n= 191): mean age 58.4 (± 12.2) CG (n= 191): mean age 57.8 (± 12) <i>Undergoing adjuvant oncological treatment</i>	Resistance, endurance and mobility exercise programme Control group: usual care (no further intervention other than leaflets provided during preoperative clinics)	» Upper limb function » Postoperative pain » Arm symptoms » Wound related complications » Lymphoedema » Quality of life <i>T0: baseline; T1: 6 weeks; T2: 6 months; T3: 12 months</i>	The exercise programme improved upper limb function, postoperative pain, arm symptoms, and physical quality of life at 12 months, compared with the control condition.	An early, structured, progressive exercise is safe and clinically effective for women at high risk of developing shoulder and upper limb problems after non-reconstructive breast surgery.
Edmunds et al., 2020 Australia and New Zealand RADAR trial	Long-term prostate cancer survivors (n= 100) EG (n= 20): mean age 71.9 (± 5.6) CG (n= 50) mean age: 71.5 (± 7.2) <i>Survivor phase</i>	Resistance and endurance exercise programme Control group: usual care with a general recommendation to perform 150 of moderate physical exercise per week with printed material	» Cardiorespiratory fitness » Lower-body functional performance » Muscle strength » Quality of life » Body composition » Biomarkers <i>T0: baseline; T1: 6 months; T2: 12 months</i>	The exercise programme improved cardiorespiratory fitness, lower-body function, muscle strength, self-reported physical functioning and appendicular skeletal muscle, compared with the control condition (T₁). Most benefits were maintained in the long-term (T₂).	Supervised exercise training in long-term prostate cancer survivors is more effective than physical activity educational material for improving a broad range of physical health outcomes.
Gordon et al., 2017	Breast cancer women after surgery (n= 194)	Resistance and endurance	» Quality of life	There were significant between-	Exercise can be considered as a

Gordon et al., 2020 Australia EfH trial	EG1 (n= 67): mean age 51.2 ($\pm$ 8.8) EG2 (n= 67): mean age 52.2 ($\pm$ 8.6) CG (n= 60): mean age 53.9 ($\pm$ 7.7) <i>Undergoing adjuvant oncological treatment</i>	exercise programme delivered face-to-face (EG1) or by telephone (EG2) Control group: no intervention, only information related to exercises following breast cancer	» Treatment-related symptoms: fatigue, menopausal symptoms, neuropathic pain and lymphoedema » Cardiorespiratory fitness » Muscle strength <i>T0: baseline; T1: 6 weeks; T2: 6 months; T3: 12 months</i>	group differences in QoL, fitness and fatigue in favour of both EG. Trends observed for the treatment groups were similar.	form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.
Haines et al., 2010 Australia	Breast cancer women after surgery (n= 89) EG (n= 46): mean age 55.9 ($\pm$ 10.5) CG (n= 47): mean age 54.2 ($\pm$ 11.5) <i>Undergoing adjuvant oncological treatment</i>	Resistance, endurance and balance exercise programme Control group: sham flexibility and relaxation exercises	» Quality of life » Upper limb swelling » Body composition » Cancer-related fatigue » General physical capacity: endurance, strength, balance and shoulder range of motion (ROM) <i>T0: baseline; T1: 3 months; T2: 6 months; and T3: 12 months</i>	There were significant between-group differences in QoL, physical function and upper limb swelling at T1 in favour of both EG. These improvements were not sustained beyond this point.	Provision of multimodal exercise programmes will improve the short-term health of women undergoing adjuvant therapy.
May et al., 2017	Breast and colon cancer (n= 194)	Resistance and endurance	» Cancer-related fatigue » Quality of life	Breast cancer: There were significant between-	Exercise early during treatment of breast and colon

Netherlands PACT trials	EG breast cancer (n= 87): mean age 50.0 (± 7.9) EG colon cancer (n= 14): mean age 57.4 (± 11.2) CG breast cancer (n= 78): mean age 49.4 (± 7.6) CG colon cancer (n= 15): mean age 59.1 (± 8.9) <i>Undergoing adjuvant oncological treatment</i>	exercise programme To be physically active for at least 30 min a day/3 days a week Control group: usual care. Maintainance of habitual physical activity pattern	» Cardiorespiratory fitness » Muscle strength » Body mass index » Physical activity level <i>T0: baseline; T1: 18 weeks; T2: 36 weeks</i>	group differences in physical fatigue (T1), cardiorespiratory fitness (T1) and muscle strength (T1) in favour of the EG. Colon cancer: There were significant between-group differences in physical fatigue (T1 and T2) and quality of life (T1 and T2) in favour of the EG.	cancer can be recommended.
Mewes et al., 2015 Netherlands	Breast cancer (n= 213) EG1 (n= 104): mean age 47.7 (± 5.6) EG2 (n=109): mean age 48.2 (± 5.7) CG (n= 103): mean age 47.8 (± 6) <i>Survivor phase</i>	EG1: endurance exercise programme (60-80% VO_{2max}) EG2: cognitive behavioural therapy (CBT) CG: waiting list	» Endocrine symptoms » Perceived burden of hot flashes/night sweats » Quality of life <i>T0: baseline; T1: 12 weeks; T2: 6 months follow-up</i>	There were significant overall effects favoring the intervention groups in all outcomes (T0 and T2)	Physical exercise and CBT can have salutary effects on endocrine symptoms and, to a lesser degree, on sexuality and physical functioning of patients with breast cancer experiencing treatment-induced menopause.

Schouten et al., 2025 Netherlands PREFERABLE-EFFECT trial	Metastatic breast cancer (n= 357) EG (n= 178): mean age 54.9 ($\pm$11.6) CG (n=179): mean age 55.9 ($\pm$10.7) <i>Undergoing adjuvant oncological treatment</i>	Resistance, endurance and balance exercise programme Control group: usual care, supplemented with general activity advice and an activity tracker	» Physical fatigue » Quality of life <i>T0: baseline; T1: 3 months; T2: 6</i>	Exercise resulted in significant positive effects on both primary outcomes. Physical fatigue was significantly lower QoL significantly higher in the exercise group than in the control group at 6 months	Supervised exercise has positive effects on physical fatigue and QoL in patients with metastatic breast cancer and should be recommended as part of supportive care.
van Dongen et al., 2019 Netherlands EXIST trial	Multiple myeloma or lymphoma (n= 109) EG (n= 54): mean age 52 ($\pm$11) CG (n=55): mean age 53 ($\pm$12) <i>Undergoing adjuvant oncological treatment</i>	Resistance and endurance exercise programme Control group: usual care It varied according to patients' and physicians' preferences. Control group patients were not restricted in their	» Cardiorespiratory fitness » Handgrip strength » Cancer-related fatigue » Quality of life <i>T0: baseline; T1: 18 weeks; T2: 12 months</i>	No statistically significant differences were found between the intervention and control group at short and long-term.	The lack of significant intervention effects may relate to suboptimal timing of intervention delivery, contamination in the control group and/or suboptimal compliance to the prescribed exercise intervention.

		physical activities or in their use of healthcare services.			
--	--	---	--	--	--

Abbreviations:

BCS: behaviour change support; **CBT:** cognitive behavioural therapy; **CG:** control group; **EG:** experimental group; **EfH:** Exercise for Health; **HI:** high-intensity; **LMI:** low-to-moderate intensity; **ROM:** range of motion; **QoL:** quality of life.

3.5 Economic analysis description

Nine of the ten economic evaluations performed a cost-effectiveness analysis and/or a cost-utility analysis. Only Ax et al. (2022) conducted a cost analysis (**Table 5**). The most common outcome measure used in cost-effectiveness assessments was Quality-Adjusted Life-Years (QALYs) (Bruce et al., 2021; Edmunds et al., 2020; Gordon et al., 2017; Gordon et al., 2020; Haines et al., 2010; May et al., 2017; Mewes et al., 2015; Schouten et al., 2025, van Dongen et al., 2019). In addition, Mewes et al. (2015) used measures of relevant symptom reduction (menopausal symptoms in breast cancer survivors) as the primary outcome for their cost-effectiveness analysis, rather than QALYs. They also calculated the Number Needed to Treat (NNT) to achieve this difference. Van Dongen et al. (2019) also included other clinical outcomes such as physical fitness (cardiorespiratory fitness, grip strength) and fatigue in their cost-effectiveness analyses, in addition to QALYs.

Regarding the perspective of the economic evaluation, five of the ten reports adopted a societal perspective in the economic analysis, which is the broadest and includes costs to the health system, the intervention and society (such as lost productivity) (Ax et al., 2022; Edmunds et al., 2020; Haines et al., 2010; May et al., 2017; van Dongen et al., 2019). Others used a health system perspective (Bruce et al., 2021; Edmunds et al., 2020), which focuses on costs to the health system. One included sensitivity analysis from a social perspective (Schouten et al. 2025) and two of the studies focused on a broad perspective covering healthcare providers, patients, and government (Gordon et al., 2017; Gordon et al., 2020). The time horizon is another determinant of the results of the economic analysis and in our case, it ranged from six months (Ax et al., 2022) to eight years (Gordon et al., 2020). A more detailed description of the economic analysis can be found in **Table 6**.

Table 5. Description of economic methods.

Cost-effectiveness analysis (CEA)

- The results of the intervention are measured in natural units (life years gained or number of patients surviving) by the difference between the results obtained in the intervention group versus the control group.
 - The main indicator for decision-making is the Incremental Cost-Effectiveness Ratio (ICER), which is calculated as the difference in total costs divided by the difference in the specific outcome measure between the intervention and the comparator.
 - The results should be read as the additional cost that is necessary to achieve one more year of life or one more survivor.
-

Cost-utility analysis (CUA)

- The CUA is a specific type of CEA where the health outcome is measured in generic units that combine quantity and quality of life gained.
 - The most common outcome measure is Quality-Adjusted Life-Years (QALYs), which are obtained from measures of health-related quality of life, such as those derived from cancer-specific questionnaires, the EQ-5D (EQ-5D-3L or EQ-5D-5L) or the SF-36.
 - The ICER in a CUA is expressed as the additional cost that needs to be incurred to achieve an additional unit of QALY gained.
 - The CUA is useful for comparing the cost-effectiveness of interventions targeting different health conditions, as QALYs provide a common metric.
 - Outcomes are often benchmarked against willingness-to-pay (WTP) thresholds for a QALY. This benchmark is derived using statistical estimation procedures and is different for different countries and years.
 - Intervention is considered 'dominant' if it is simultaneously less costly and more effective (generates more QALYs) than the comparator.
-

Costs analysis

- It quantifies and compares the costs and resources used by the intervention group versus the control group, without going into health outcomes.
 - The analysis is done from a social perspective and includes those of exercise intervention, medical care and lost productivity.
-

Table 6. Summary of the characteristics of the economic analysis.

Author(s), year Country	Main methodology used	Outcome indicator	Analysis perspective	Relevant additional notes
Ax et al., 2022 Sweden	Cost Analysis	Resource use (outpatient visits, hospitalisation days, medications, sick days) and total/disaggregated costs	Social, including healthcare system costs and productivity losses	Focused on quantifying and comparing costs and resource use. Health outcome metrics such as QALYs or cost per unit of specific effect were not included. ANCOVA analysis and t-tests were used for comparisons. No discounting was applied for comparisons <2 years.
Bruce et al., 2021 United Kingdom	Cost-Utility Analysis (CUA)	Quality-Adjusted Life Years (QALYs) (derived from the EQ-5D-5L), Incremental cost per QALY gained, Incremental Net Monetary Benefit	NHS and Personal Social Services	Analysis within a randomised controlled trial (RCT) with a 12-month time horizon. No discounting was applied. Multiple imputation was used for missing data. Cost-effectiveness acceptability curves (CEACs) were used.
Edmunds et al., 2020 Australia and New Zealand	Cost-Effectiveness Analysis (CEA), specifically CUA	QALYs (estimated from the SF-36/SF-6D), Incremental cost per QALY gained	Healthcare-Payor (baseline analysis) and Social (sensitivity analysis)	Analysis within a trial with a 6-month time horizon. No discounting was applied. Maximum likelihood and multiple imputation were used for missing QALYs. Cost-effectiveness acceptability curves (CEACs) and a cost-effectiveness plane were presented.
Gordon et al., 2017 Australia	Cost-Effectiveness Analysis, including CUA	QALYs (derived from the EQ-5D-3L), Incremental cost per "improver"	Broad (covering healthcare providers, patients, and government)	Evaluated cost-effectiveness versus usual care. Time horizon was 12 months. One-way and probabilistic sensitivity analyses were performed.

Gordon et al., 2020 Australia	Cost-Effectiveness Analysis using a Markov model	QALYs, Life Years, Incremental Cost-Effectiveness Ratio (ICER)	Implicitly broad/social (uses varied data, including mortality and recurrence)	Cohort-based analysis of the remaining life span. A 5% annual discount rate was applied to costs, QALYs, and life years. Adherence to CHEERS guidelines. Use of one-way and probabilistic sensitivity analyses.
Haines et al., 2010 Australia	Cost-Utility Analysis (CUA)	QALYs (derived from the utility component of the EQ-5D), Outcomes based on the VAS component of the EQ-5D	Social	Economic evaluation over a 6-month time horizon. Cost-effectiveness acceptability analysis was performed using bootstrap. Linear mixed models were used to analyse HQoL outcomes.
May et al., 2017 Netherlands	Cost-Effectiveness Analysis, specifically CUA	Adjusted QALYs, Incremental Cost-Effectiveness Ratio (ICER)	Social	Prospective economic evaluation in an RCT. The time horizon is not explicitly detailed in the abstract, but appears to encompass the intervention (18 weeks) plus follow-up. A "bottom-up" microcosting method was used for intervention costs. Use of cost-effectiveness acceptability curves and planes.
Mewes et al., 2015 Netherlands	Cost-Effectiveness Analysis (CEA) and Cost-Utility Analysis (CUA) using a Markov model	Incremental cost per "improvement" (on FACT-ES, HFRS scales), Costs per QALY gained	Dutch healthcare system	Analysis based on an RCT. Use of a 5-year Markov model. Discounting was applied to costs (4%) and effects (1.5%). One-way and probabilistic sensitivity analyses were performed. Use of cost-effectiveness acceptability curves and planes.
Schouten et al., 2025 Netherlands	Cost-Utility Analysis (CUA)	QALYs (derived from the EQ-5D-5L), Incremental cost per QALY gained	Social (base case) and Healthcare (scenario)	Analysis in a multinational RCT. 9-month time horizon. Use of the bottom-up method for intervention costs. Multiple imputation was used for missing data. Bootstrapping, cost-effectiveness planes, and acceptability curves were used. "Dominant" interventions

				(least expensive and most effective) were identified.
Van Dongen et al., 2019 Netherlands	Cost-Effectiveness Analysis, including CUA	Incremental cost per unit of natural outcomes (e.g., cardiorespiratory fitness, grip strength, fatigue), Costs per QALY gained (derived from the EQ-5D-3L)	Social	Long-term cost-effectiveness assessment (1-year post-intervention). Microcosting was used for intervention costs. Discounting was applied to post-1-year costs (4%). Multiple imputation was used for missing data. Bootstrapping, cost-effectiveness planes, and acceptability curves were used.

Abbreviations:

CEA: cost-effectiveness analysis; **CHEERS:** Consolidated Health Economic Evaluation Reporting Standards; **CUA:** cost-utility analysis; **EQ-5D-3L:** Euroqol -five dimensions -three levels; **EQ-5D-5L:** Euroqol -five dimensions -five levels; **FACT-ES:** Functional Assessment of Cancer Therapy – Endocrine Symptoms; **HFRS:** Hospital Frailty Risk Score; **HQoL:** health related quality of life; **ICER:** incremental cost utility ratio; **NHS:** National Health Service; **QALYs:** quality-adjusted life-years; **RCT:** randomised controlled trial; **SF-36:** short form health survey; SF-6D: short form-six dimensions health survey; **VAS:** visual analogue scale.

3.6 Results of economic evaluations: cost-effectiveness

3.6.1 Costs

Almost all studies reported the cost of the exercise intervention, detailing its components (professionals, facilities, materials). In general, direct results on whether exercise is more costly or saves money are inconsistent. Some studies suggest that exercise may be less costly or have similar costs to usual care (May et al., 2017-colon cancer; Schouten et al., 2025). In these cases, the cost of the intervention may be offset by savings in medical care or improvements in productivity. Other studies found that exercise was associated with similar total costs (Ax et al., 2022; Van Dongen et al., 2019), but with trade-offs between different types of costs (e.g. higher health care costs offset by lower productivity/informal care costs). Ax et al. (2022) also reported savings in disability pension costs in favour of exercise intervention. In contrast, May et al. (2017) found that exercise intervention was associated with higher costs in breast cancer, with no clear benefit to quality of life, while Edmunds et al. (2020) reported no evidence of cost savings in subsequent resource use (drugs, health services) or loss of productivity in prostate cancer survivors. Finally, Mewes et al. (2015) concluded that exercise had slightly higher incremental costs than usual care and higher than cognitive behaviour therapy (CBT) to achieve certain outcomes, although the total 5-year costs were similar to CBT (**Table 7**).

3.6.2 Incremental cost-effectiveness ratios

The heterogeneity described in cost estimates, outcome measures, patient populations, study designs, intervention characteristics and health care systems make comparisons difficult. Therefore, in general, there was no clear trend in the cost-effectiveness results for exercise-based interventions in the cancer population.

- *Cost-effective or dominant:*

Four of the ten trials reported results in favour of exercise interventions. May et al. (2017) found that exercise was cost-effective and dominant (least costly and most effective) for patients with colorectal cancer, with a 100% probability of being cost-effective. Schouten et al. (2025) found that supervised exercise was dominant (more effective and at similar or lower cost) from a societal perspective for patients with metastatic breast cancer in both 1:1 and 1:4 supervised settings. The costs of the intervention were offset by health care and productivity savings, and the intervention was highly likely to be cost-effective (65%-91% at the willingness-to-pay threshold of €20,000/QALY). Similarly, Bruce et al. (2021) reported that the likelihood of the intervention being cost-effective increased significantly when the costs of other cancer treatments were removed. Finally, Haines et al. (2010) reported that the intervention had higher costs for medical care, but significantly lower costs for unpaid productivity and informal care (**Table 7**).

- *No cost-effective:*

Four of the ten trials reported results that did not clearly support the cost-effectiveness of exercise interventions. May et al. (2017) found that exercise was not cost-effective for breast cancer patients, as it was associated with higher costs without a clear effect on quality of life. The probability of being cost-effective was low (2% at €20,000/QALY). Similarly, Van Dongen et al. (2019) found a low probability of cost-effectiveness for exercise after stem cell transplantation, and the overall cost difference remained in favour of the control group in the main analysis. Finally, Gordon et al. (2017, 2020) showed different ICER results in their sensitivity analyses, including scenarios where 'usual care dominates' (**Table 7**).

Table 7. Summary of the main economic findings.

Author(s), year Country	Currency, cost year	Main costs	Summary of findings	Time Horizon	Analysis perspective	Keypoints
Ax et al., 2022 Sweden	EUR (Oct 2021)	Total Social Costs; Disability Pension Costs	No significant difference in total social costs between the exercise group (RCT) and the usual care group (UC) at 18 months. Significantly lower disability pension costs in the RCT exercise group.	18 months	Social	Exercise did not generate significant differences in total long-term social costs, although there were savings in disability pension costs. The cost of the exercise intervention was higher than in comparable studies.
Bruce et al., 2021 United Kingdom	GBP (2015)	Use of secondary care resources (inpatient, outpatient)	Uncertainty in cost-effectiveness estimates was driven by the large and variable costs of other cancer treatments (e.g. adjuvant chemotherapy).	12 months	NHS and Personal Social Services	By eliminating the costs of other cancer treatments, the likelihood of the intervention being cost-effective increased significantly.
Edmunds et al., 2020 Australia and New Zealand	AU\$ (2018)	Intervention Cost; Incremental Cost	Cost of physical activity intervention over 6 months (health care payer perspective): AU\$550. Incremental cost of intervention (vs. usual care): AU\$546. Incremental cost (societal perspective in SA): AU\$1012.	6 months	Health Care Payer (Insurer)	No evidence was found to support cost savings in subsequent resource use (medicines, health services) or productivity losses.
Gordon et al., 2017 Australia	AU\$ (2014)	Incremental Cost- Effectiveness Ratios (ICERs)	Report ICERs in AU\$ 2014. (E.g.: Cost per QALY earned \$90,842 in the Private EP model, \$105,231 in the Service Provider - Base Case model).	12 months	Broad (providers, patients, government)	Usual care dominates (less costly, more effective) in some sensitivity analysis scenarios.

Gordon et al., 2020 Australia	AU\$ (2019/20)	Incremental Cost-Effectiveness Ratios (ICERs) (model-based)	Report ICERs in AU\$ 2019/2020 derived from model simulations (e.g. ICER Base Case \$21,247 per QALY earned).	Long term (Model)	Social (implicit in the costs included)	The sensitivity analysis shows the variability in the ICER depending on the model parameters.
Haines et al., 2010 Australia	AU\$ (2006)	Average Costs per Group (Programme, Medical Care, Productivity)	Mean (SD) cost over 6 months: Intervention \$24,397 (1322), Control \$24,119 (1430). Adjusted cost difference €529 (95% CI - 3205 to 4452), not significant.	6 months	Broad (includes provisioning, medical care, productivity)	The intervention had higher costs in medical care, but significantly lower costs in unpaid productivity and informal care.
May et al., 2017 Netherlands	EUR (2011)	Average Total Costs (Societal, Health Care) by Group	Breast Cancer: Societal Intervention €25,105 (SD 10,403), Societal Control €22,215 (SD 8652). Incremental (Intervention-Control) €2912. Colon Cancer: Societal Intervention €21,086 (SD 7037), Societal Control €25,391 (SD 7131). Incremental (Intervention-Control) - €4321. Cost per exercise session per patient: €22.18.	9 months	Social (health care)	Cost-effective and dominant (cheaper, more effective) for colon cancer. Not cost-effective for breast cancer (higher costs with no clear effects).
Mewes et al., 2015 Netherlands	EUR (2010/11)	Intervention Costs; Total Costs (5-year model); Incremental Costs	Intervention costs: CBT €190, EP €197. Total costs over 5 years: CBT €2,983, PE €2,983, WLC €2,798. Incremental Costs (vs WLC): CBT €184, PE €185.	5 years (Model)	Dutch health system	CBT probably most cost-effective in alleviating menopausal symptoms, followed by PE.
Schouten et al., 2025 Netherlands	EUR (2021)	Average Total Costs by Group; Adjusted Difference	Average Total Costs: CG €9,700, EG (1:1) €9,568, EG (1:4) €8,482. Adjusted Difference (EG vs CG): -€163 (1-to-1), -€1,249 (1-to-4).	9 months	Social	The supervised exercise (both 1:1 and 1:4) was dominant (more effective and less costly) from a societal perspective.

Van Dongen et al., 2019 Netherlands	EUR (2014)	Cost of Intervention per Patient; Average Total Costs per Group	Intervention cost per patient: €1340. Average Total Costs: Intervention €24,397, Control €24,119. Adjusted cost difference €529 (95% CI -3205 to 4452), not significant.	>1 year (follow-up)	Social	Total social costs were higher in the intervention group but the difference was not significant. Health care costs were significantly higher in the intervention group, but unpaid productivity and informal care costs were significantly lower.
--	------------	---	--	---------------------	--------	---

Abbreviations:

AU\$: Australian dollar; **CBT:** cognitive behavioural therapy; **CG:** control group; **EG:** experimental group; **EUR:** euro; **ICERs:** incremental cost-effectiveness ratios; **NHS:** National Health Service; **PE:** physical exercise; **QALYs:** quality-adjusted life-years; **RCT:** randomised controlled trial; **SD:** standard deviation; **UC:** usual care; **WLC:** waiting list control.

4. Conclusions

This report aimed to synthesise the current evidence on the cost-effectiveness of exercise therapy in the cancer population. A total of ten economic evaluations performed from 2010 to 2025 were included.

Overall, the economic analyses presented vary considerably in their scope, methodology and results. Although the evidence is still inconclusive, some studies suggest that exercise for cancer may be cost-effective or even dominant in certain populations and contexts (e.g., colorectal cancer, metastatic breast cancer), with the costs of the intervention offset by savings in health care or productivity (particularly reduced long-term disability pensions). Other studies found no significant cost savings or cost-effectiveness in different populations or with shorter time horizons.

In conclusion, although considerable efforts have been made to evaluate the economic aspects of exercise in oncology, the current scarcity of economic studies, along with the heterogeneity of their methodologies, study populations and time horizons, makes it difficult to draw general conclusions or directly compare the reported cost-effectiveness. Evidence suggests that the economic impact may be variable, depending on factors such as the type of cancer, the timing of the intervention and the extent of the costs considered (social vs medical care perspective). Finally, it is recommended that future economic evaluations on this topic be conducted, as they can provide valuable insights and inform policy decisions.

References

- Al-Bayati, O., Hasan, A., Pruthi, D., Kaushik, D., & Liss, M. A. (2019). Systematic review of modifiable risk factors for kidney cancer. *Urologic Oncology: Seminars and Original Investigations*, 37(6), 359–371. <https://doi.org/10.1016/j.urolonc.2018.12.008>
- Ax, A. K., Husberg, M., Johansson, B., Demmelmaier, I., Berntsen, S., Sjövall, K., Börjeson, S., Nordin, K., & Davidson, T. (2022). Long-term resource utilisation and associated costs of exercise during (neo)adjuvant oncological treatment: The Phys-Can project. *Acta Oncologica*, 61(7), 888–896. <https://doi.org/10.1080/0284186X.2022.2075238>
- Behrens, G., & Leitzmann, M. F. (2013). The association between physical activity and renal cancer: Systematic review and meta-analysis. *British Journal of Cancer*, 108(4), 798–811. <https://doi.org/10.1038/bjc.2013.37>
- Behrens, G., Jochem, C., Keimling, M., Ricci, C., Schmid, D., & Leitzmann, M. F. (2014). The association between physical activity and gastroesophageal cancer: Systematic review and meta-analysis. *European Journal of Epidemiology*, 29(3), 151–170. <https://doi.org/10.1007/s10654-014-9895-2>
- Bruce, J., Mazuquin, B., Canaway, A., Hossain, A., Williamson, E., Mistry, P., Lall, R., Petrou, S., Lamb, S. E., Rees, S., Padfield, E., Vidya, R., Thompson, A. M., & Prevention of Shoulder Problems Trial (PROSPER) Study Group. (2021). Exercise versus usual care after non-reconstructive breast cancer surgery (UK PROSPER): Multicentre randomised controlled trial and economic evaluation. *BMJ*, 375, e066542. <https://doi.org/10.1136/bmj-2021-066542>

Bui, T. T., Park, E., Kang, H. Y., Kim, B., & Oh, J. K. (2025). Changes in physical activity and mortality risk among Korean cancer survivors: A population-based cohort study. *Cancer Epidemiology, Biomarkers & Prevention*. Advance online publication. <https://doi.org/10.1158/1055-9965.EPI-24-1908>

Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., Dempsey, P. C., DiPietro, L., Ekelund, U., Firth, J., Friedenreich, C. M., Garcia, L., Gichu, M., Jago, R., Katzmarzyk, P. T., ... Willumsen, J. F. (2020). World Health Organization 2020 guidelines on physical activity and sedentary behaviour. *British Journal of Sports Medicine*, 54(24), 1451–1462. <https://doi.org/10.1136/bjsports-2020-102955>

Campbell, K. L., Winters-Stone, K. M., Wiskemann, J., May, A. M., Schwartz, A. L., Courneya, K. S., Zucker, D. S., Matthews, C. E., Ligibel, J. A., Gerber, L. H., Morris, G. S., Patel, A. V., Hue, T. F., Perna, F. M., & Schmitz, K. H. (2019). Exercise guidelines for cancer survivors: Consensus statement from international multidisciplinary roundtable. *Medicine & Science in Sports & Exercise*, 51(11), 2375–2390.

Cormie, P., Zopf, E. M., Zhang, X., & Schmitz, K. H. (2017). The impact of exercise on cancer mortality, recurrence, and treatment-related adverse effects. *Epidemiologic Reviews*, 39(1), 71–92. <https://doi.org/10.1093/epirev/mxx007>

Demmelmaier, I., Brooke, H. L., Henriksson, A., Mazzoni, A. S., Bjørke, A. C. H., Igelström, H., Ax, A. K., Sjövall, K., Hellbom, M., Pingel, R., Lindman, H., Johansson, S., Velikova, G., Raastad, T., Buffart, L. M., Åsenlöf, P., Aaronson, N. K., Glimelius, B., Nygren, P., ... Nordin, K. (2021). Does exercise intensity matter for fatigue during (neo-)adjuvant cancer treatment? The Phys-Can randomized clinical trial. *Scandinavian Journal of Medicine & Science in Sports*, 31(5), 1144–1159. <https://doi.org/10.1111/sms.13930>

Dong, X., Ding, M., Yi, N., Hou, X., Zhou, C., & Yi, X. (2025). Physical activity and risk of cancer mortality in patients with and without cancer: Is there a dose-response relationship? *Supportive Care in Cancer*, 33(4), 342.

<https://doi.org/10.1007/s00520-025-09288-x>

Duijts, S. F., van Beurden, M., Oldenburg, H. S., Hunter, M. S., Kieffer, J. M., Stuiver, M. M., Gerritsma, M. A., Menke-Pluymers, M. B., Plaisier, P. W., Rijna, H., Lopes Cardozo, A. M., Timmers, G., van der Meij, S., van der Veen, H., Bijker, N., de Widt-Levert, L. M., Geenen, M. M., Heuff, G., van Dulken, E. J., ... Aaronson, N. K. (2012). Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: Results of a randomized, controlled, multicenter trial. *Journal of Clinical Oncology*, 30(33), 4124–4133.

<https://doi.org/10.1200/JCO.2012.41.8525>

Edmunds, K., Reeves, P., Scuffham, P., Galvão, D. A., Newton, R. U., Jones, M., Spry, N., Taaffe, D. R., Joseph, D., Chambers, S. K., & Tuffaha, H. (2020). Cost-effectiveness analysis of supervised exercise training in men with prostate cancer previously treated with radiation therapy and androgen-deprivation therapy. *Applied Health Economics and Health Policy*, 18(5), 727–737.

<https://doi.org/10.1007/s40258-020-00564-x>

Eriksen, M. B., & Frandsen, T. F. (2018). The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: A systematic review. *Journal of the Medical Library Association*, 106, 420–431.

Galvão, D. A., Spry, N., Denham, J., Taaffe, D. R., Cormie, P., Joseph, D., Lamb, D. S., Chambers, S. K., & Newton, R. U. (2014). A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and

radiation from TROG 03.04 RADAR. *European Urology*, 65(5), 856–864.

<https://doi.org/10.1016/j.eururo.2013.09.041>

Gonçalves, A. K., Dantas Florencio, G. L., Maisonnnette de Atayde Silva, M. J., Cobucci, R. N., Giraldo, P. C., & Cote, N. M. (2014). Effects of physical activity on breast cancer prevention: A systematic review. *Journal of Physical Activity and Health*, 11(2), 445–454. <https://doi.org/10.1123/jpah.2011-0316>

Gordon, L. G., DiSipio, T., Battistutta, D., Yates, P., Bashford, J., Pyke, C., Eakin, E., & Hayes, S. C. (2017). Cost-effectiveness of a pragmatic exercise intervention for women with breast cancer: Results from a randomized controlled trial. *Psycho-Oncology*, 26(5), 649–655.

<https://doi.org/10.1002/pon.4201>

Gordon, L. G., Eakin, E. G., Spence, R. R., Pyke, C., Bashford, J., Saunders, C., & Hayes, S. C. (2020). Cost-effectiveness analysis from a randomized controlled trial of tailored exercise prescription for women with breast cancer with 8-year follow-up. *International Journal of Environmental Research and Public Health*, 17(22), 8608. <https://doi.org/10.3390/ijerph17228608>

Gubler-Gut, B. E., Pöhlmann, J., Flatz, A., Schwenkglenks, M., & Rohrmann, S. (2021). Cost-effectiveness of physical activity interventions in cancer survivors of developed countries: A systematic review. *Journal of Cancer Survivorship*, 15(6), 961–975. <https://doi.org/10.1007/s11764-021-01002-0>

Gunnell, A. S., Joyce, S., Tomlin, S., Taaffe, D. R., Cormie, P., Newton, R. U., Joseph, D., Spry, N., Einarsdóttir, K., & Galvão, D. A. (2017). Physical activity and survival among long-term cancer survivor and non-cancer cohorts. *Frontiers in Public Health*, 5, 19. <https://doi.org/10.3389/fpubh.2017.00019>

Gupta, B., Gupta, K., Narula, K., Sharma, P., & Mittal, A. (2025). The effect of exercise on quality of life among patients and survivors of breast cancer: A systematic review and meta-analysis. *Asian Pacific Journal of Cancer*

Prevention: APJCP, 26(3), 715–723.

<https://doi.org/10.31557/APJCP.2025.26.3.715>

Haines, T. P., Sinnamon, P., Wetzig, N. G., Lehman, M., Walpole, E., Pratt, T., & Smith, A. (2010). Multimodal exercise improves quality of life of women being treated for breast cancer, but at what cost? Randomized trial with economic evaluation. *Breast Cancer Research and Treatment*, 124(1), 163–175.

<https://doi.org/10.1007/s10549-010-1126-2>

Hardefeldt, P. J., Penninkilampi, R., Edirimanne, S., & Eslick, G. D. (2018). Physical activity and weight loss reduce the risk of breast cancer: A meta-analysis of 139 prospective and retrospective studies. *Clinical Breast Cancer*, 18(4), e601–e612. <https://doi.org/10.1016/j.clbc.2017.10.010>

Hayes, S. C., Rye, S., DiSipio, T., Yates, P., Bashford, J., Pyke, C., Saunders, C., Battistutta, D., & Eakin, E. (2013). Exercise for health: A randomized, controlled trial evaluating the impact of a pragmatic, translational exercise intervention on the quality of life, function and treatment-related side effects following breast cancer. *Breast Cancer Research and Treatment*, 137(1), 175–186. <https://doi.org/10.1007/s10549-012-2331-y>

Hermelink, R., Leitzmann, M. F., Markozannes, G., Tsilidis, K., Pukrop, T., Berger, F., Baurecht, H., & Jochem, C. (2022). Sedentary behavior and cancer—An umbrella review and meta-analysis. *European Journal of Epidemiology*, 37(5), 447–460. <https://doi.org/10.1007/s10654-022-00873-6>

Hiensch, A. E., Depenbusch, J., Schmidt, M. E., Monninkhof, E. M., Pelaez, M., Clauss, D., Gunasekara, N., Zimmer, P., Belloso, J., Trevaskis, M., Rundqvist, H., Wiskemann, J., Müller, J., Sweegers, M. G., Fremd, C., Altena, R., Gorecki, M., Bijlsma, R., van Leeuwen-Snoeks, L., ... May, A. M. (2024). Supervised, structured and individualized exercise in metastatic breast cancer: A randomized controlled trial. *Nature Medicine*, 30(10), 2957–2966.

<https://doi.org/10.1038/s41591-024-03143-y>

Higgins, J., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M., & Welch, V. (2023). *Cochrane handbook for systematic reviews of interventions* (Version 6.4, August 2023). Cochrane.

Khan, N. F., Rose, P. W., & Evans, J. (2012). Defining cancer survivorship: A more transparent approach is needed. *Journal of Cancer Survivorship*, 6(1), 33–36. <https://doi.org/10.1007/s11764-011-0194-6>

Keimling, M., Behrens, G., Schmid, D., Jochem, C., & Leitzmann, M. F. (2014). The association between physical activity and bladder cancer: Systematic review and meta-analysis. *British Journal of Cancer*, 110(7), 1862–1870. <https://doi.org/10.1038/bjc.2014.77>

May, A. M., Bosch, M. J., Velthuis, M. J., van der Wall, E., Steins Bisschop, C. N., Los, M., Erdkamp, F., Bloemendal, H. J., de Roos, M. A., Verhaar, M., Ten Bokkel Huinink, D., Peeters, P. H., & de Wit, G. A. (2017). Cost-effectiveness analysis of an 18-week exercise programme for patients with breast and colon cancer undergoing adjuvant chemotherapy: The randomised PACT study. *BMJ Open*, 7(3), e012187. <https://doi.org/10.1136/bmjopen-2016-012187>

McTiernan, A., Friedenreich, C. M., Katzmarzyk, P. T., Powell, K. E., Macko, R., Buchner, D., Pescatello, L. S., Bloodgood, B., Tennant, B., Vaux-Bjerke, A., George, S. M., Troiano, R. P., Piercy, K. L., & 2018 Physical Activity Guidelines Advisory Committee. (2019). Physical activity in cancer prevention and survival: A systematic review. *Medicine and Science in Sports and Exercise*, 51(6), 1252–1261. <https://doi.org/10.1249/MSS.0000000000001937>

Mewes, J. C., Steuten, L. M., Duijts, S. F., Oldenburg, H. S., van Beurden, M., Stuiver, M. M., Hunter, M. S., Kieffer, J. M., van Harten, W. H., & Aaronson, N. K. (2015). Cost-effectiveness of cognitive behavioral therapy and physical exercise for alleviating treatment-induced menopausal symptoms in breast cancer patients. *Journal of Cancer Survivorship*, 9(1), 126–135. <https://doi.org/10.1007/s11764-014-0396-9>

Namiranian, N., Moradi-Lakeh, M., Razavi-Ratki, S. K., Doayie, M., & Nojomi, M. (2014). Risk factors of breast cancer in the Eastern Mediterranean Region: A systematic review and meta-analysis. *Asian Pacific Journal of Cancer Prevention*, 15(21), 9535–9541. <https://doi.org/10.7314/apjcp.2014.15.21.9535>

National Cancer Institute. (2020). Physical activity and cancer. *National Cancer Institute*. Retrieved April 6, 2025, from https://www.cancer.gov/about-cancer/causes-prevention/risk/obesity/physical-activity-fact-sheet?utm_source=chatgpt.com#what-is-known-about-the-relationship-between-physical-activity-and-cancer-risk

Neil-Sztramko, S. E., Boyle, T., Milosevic, E., Nugent, S. F., Gotay, C. C., & Campbell, K. L. (2017). Does obesity modify the relationship between physical activity and breast cancer risk? *Breast Cancer Research and Treatment*, 166(2), 367–381. <https://doi.org/10.1007/s10549-017-4449-4>

Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ*, 372, n71. <https://doi.org/10.1136/bmj.n71>

Perrier, F., Ahimbisibwe, A., Ghiasvand, R., Rueegg, C. S., Green, A. C., Borch, K. B., Braaten, T., Weiderpass, E., Valberg, M., Robsahm, T. E., & Veierød, M. B. (2025). Physical activity and mortality in melanoma patients within the Norwegian Women and Cancer study (NOWAC). *International Journal of Cancer*. Advance online publication. <https://doi.org/10.1002/ijc.35430>

Persoon, S., ChinAPaw, M. J. M., Buffart, L. M., Liu, R. D. K., Wijermans, P., Koene, H. R., Minnema, M. C., Lugtenburg, P. J., Marijt, E. W. A., Brug, J., Nollet, F., Kersten, M. J. (2017). Randomized controlled trial on the effects of a supervised high intensity exercise program in patients with a hematologic malignancy treated with autologous stem cell transplantation: Results from the

EXIST study. *PLOS ONE*, 12(7), e0181313.

<https://doi.org/10.1371/journal.pone.0181313>

Pizot, C., Boniol, M., Mullie, P., Koechlin, A., Boniol, M., Boyle, P., & Autier, P. (2016). Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies. *European Journal of Cancer*, 52, 138–154. <https://doi.org/10.1016/j.ejca.2015.10.063>

Poorolajal, J., Moradi, L., Mohammadi, Y., Cheraghi, Z., & Gohari-Ensaf, F. (2020). Risk factors for stomach cancer: A systematic review and meta-analysis. *Epidemiology and Health*, 42, e2020004. <https://doi.org/10.4178/epih.e2020004>

Poorolajal, J., Heidaramoghis, F., Karami, M., Cheraghi, Z., Gohari-Ensaf, F., Shahbazi, F., Zareie, B., Ameri, P., Sahraee, F. (2021). Factors for the primary prevention of breast cancer: A meta-analysis of prospective cohort studies. *Journal of Research in Health Sciences*, 21(3), e00520. <https://doi.org/10.34172/jrhs.2021.57>

Psaltopoulou, T., Ntanas-Stathopoulos, I., Tzanninis, I. G., Kantzanou, M., Georgiadou, D., & Sergentanis, T. N. (2016). Physical activity and gastric cancer risk: A systematic review and meta-analysis. *Clinical Journal of Sport Medicine*, 26(6), 445–464. <https://doi.org/10.1097/JSM.0000000000000316>

Puzzono, M., Mannucci, A., Grannò, S., Zuppardo, R. A., Galli, A., Danese, S., Cavestro, G. M. (2021). The role of diet and lifestyle in early-onset colorectal cancer: A systematic review. *Cancers (Basel)*, 13(23), 5933. <https://doi.org/10.3390/cancers13235933>

Rodríguez Cintas, M., Márquez, S., & González-Gallego, J. (2021). Systematic review: The impact of physical activity on risk and health-related bladder cancer. *Bladder Cancer*, 7, 355–364. <https://doi.org/10.3233/BLC-200406>

Schmid, D., Behrens, G., Keimling, M., et al. (2015). A systematic review and meta-analysis of physical activity and endometrial cancer risk. *European Journal of Epidemiology*, 30(5), 397–412.

Schouten, A. E. M., Hiensch, A. E., Frederix, G. W. J., Monninkhof, E. M., Schmidt, M. E., Clauss, D., Gunasekara, N., Belloso, J., Trevaskis, M., Rundqvist, H., Wiskemann, J., Müller, J., Sweegers, M. G., Fremd, C., Altena, R., Bijlsma, R. M., Sonke, G., Lahuerta, A., Mann, G. B., Francis, P. A., Richardson, G., Malter, W., Kufel-Grabowska, J., van der Wall, E., Aaronson, N. K., Senkus, E., Urruticoechea, A., Zopf, E. M., Bloch, W., Stuiver, M. M., Wengstrom, Y., Steindorf, K., van der Meulen, M. P., & May, A. M. (2025). Supervised exercise for patients with metastatic breast cancer: A cost-utility analysis alongside the PREFERABLE-EFFECT randomized controlled trial. *Journal of Clinical Oncology*, 43(11), 1325–1336. <https://doi.org/10.1200/JCO-24-01441>

Shaw, E., Farris, M. S., Stone, C. R., Derksen, J. W. G., Johnson, R., Hilsden, R. J., Friedenreich, C. M., & Brenner, D. R. (2018). Effects of physical activity on colorectal cancer risk among family history and body mass index subgroups: A systematic review and meta-analysis. *BMC Cancer*, 18(1), 71. <https://doi.org/10.1186/s12885-017-3970-5>

Travier, N., Velthuis, M. J., Steins Bisschop, C. N., van den Buijs, B., Monninkhof, E. M., Backx, F., Los, M., Erdkamp, F., Bloemendal, H. J., Rodenhuis, C., de Roos, M. A., Verhaar, M., ten Bokkel Huinink, D., van der Wall, E., Peeters, P. H., & May, A. M. (2015). Effects of an 18-week exercise programme started early during breast cancer treatment: A randomised controlled trial. *BMC Medicine*, 13, 121. <https://doi.org/10.1186/s12916-015-0362-z>

van Dongen, J. M., Persoon, S., Jongeneel, G., Bosmans, J. E., Kersten, M. J., Brug, J., Nollet, F., Chinapaw, M. J. M., & Buffart, L. M. (2019). Long-term

effectiveness and cost-effectiveness of an 18-week supervised exercise program in patients treated with autologous stem cell transplantation: Results from the EXIST study. *Journal of Cancer Survivorship*, 13(4), 558–569.

<https://doi.org/10.1007/s11764-019-00775-9>

van Vulpen, J. K., Velthuis, M. J., Steins Bisschop, C. N., Travier, N., Van Den Buijs, B. J., Backx, F. J., Los, M., Erdkamp, F. L., Bloemendal, H. J., Koopman, M., De Roos, M. A., Verhaar, M. J., Ten Bokkel-Huinink, D., Van Der Wall, E., Peeters, P. H., & May, A. M. (2016). Effects of an exercise program in colon cancer patients undergoing chemotherapy. *Medicine and Science in Sports and Exercise*, 48(5), 767–775. <https://doi.org/10.1249/MSS.0000000000000855>

Wild, C. P., Weiderpass, E., & Stewart, B. W. (Eds.). (2020). *World Cancer Report: Cancer Research for Cancer Prevention*. International Agency for Research on Cancer. Available from <http://publications.iarc.fr/586>

Williams, P. T. (2014). Reduced risk of incident kidney cancer from walking and running. *Medicine and Science in Sports and Exercise*, 46(2), 312–317.

<https://doi.org/10.1249/MSS.0b013e3182a4e89c>

World Health Organization. (2020). WHO guidelines on physical activity and sedentary behaviour (electronic version). World Health Organization.

https://www.who.int/health-topics/cancer#tab=tab_2

Supplementary material

Table S1. List of excluded records with reasons.

Reason 1. Control group received exercise intervention (C).	
1.	Watzek JT, Gordon LG, Sandler CX, Spence RR, Vagenas D, Pyke C, Hayes SC. A cost-consequences analysis of the SAFE trial: a comparative, effectiveness trial evaluating high- versus low-supervision of an exercise intervention for women with breast cancer. <i>Breast Cancer</i> . 2023 Mar;30(2):249-258. doi: 10.1007/s12282-022-01418-1.
2.	Ax AK, Husberg M, Johansson B, Demmelmaier I, Berntsen S, Sjövall K, Börjeson S, Nordin K, Davidson T. Cost-effectiveness of different exercise intensities during oncological treatment in the Phys-Can RCT. <i>Acta Oncol</i> . 2023 Apr;62(4):414-421. doi: 10.1080/0284186X.2023.2200149.
3.	Alibhai SMH, Papadopoulos E, Mina DS, Ritvo P, Tomlinson G, Sabiston CM, Durbano S, Bremner KE, Chiarotto J, Matthew A, Warde P, O'Neill M, Culos-Reed SN. Home-based versus supervised group exercise in men with prostate cancer on androgen deprivation therapy: A randomized controlled trial and economic analysis. <i>J Geriatr Oncol</i> . 2024 Jan;15(1):101646. doi: 10.1016/j.jgo.2023.101646.
4.	Kampshoff CS, van Dongen JM, van Mechelen W, Schep G, Vreugdenhil A, Twisk JWR, Bosmans JE, Brug J, Chinapaw MJM, Buffart LM. Long-term effectiveness and cost-effectiveness of high versus low-to-moderate intensity resistance and endurance exercise interventions among cancer survivors. <i>J Cancer Surviv</i> . 2018 Jun;12(3):417-429. doi: 10.1007/s11764-018-0681-0.
5.	van Waart, H., van Dongen, J. M., van Harten, W. H., Stuiver, M. M., Huijsmans, R., Hellendoorn-van Vreeswijk, J. A. J. H., Sonke, G. S., & Aaronson, N. K. (2018). Cost-utility and cost-effectiveness of physical exercise during adjuvant chemotherapy. <i>The European journal of health economics: HEPAC: health economics in prevention and care</i> , 19(6), 893–904. doi: 10.1007/s10198-017-0936-0.
Reason 2. Multimodal intervention or exercise intervention does not meet our selection criteria (I).	
6.	Perrier L, Foucaut AM, Morelle M, Touillaud M, Kempf-Lépine AS, Heinz D, Gomez F, Meyrand R, Baudinet C, Berthouze S, Reynes E, Carretier J, Guillemaut S, Pérol D, Trédan O, Philip T, Bachmann P, Fervers B. Cost-effectiveness of an exercise and nutritional intervention versus usual nutritional care during adjuvant treatment for localized breast cancer: the PASAPAS

	randomized controlled trial. Support Care Cancer. 2020 Jun;28(6):2829-2842. doi: 10.1007/s00520-019-05078-4.
7.	Shih ST, Butow P, Bowe SJ, Thewes B, Turner J, Gilchrist J, Mihalopoulos C; ConquerFear research group. Cost-effectiveness of an intervention to reduce fear of cancer recurrence: The ConquerFear randomized controlled trial. Psychooncology. 2019 May;28(5):1071-1079. doi: 10.1002/pon.5056.
8.	Viamonte, S. G., Tavares, A., Alves, A. J., Joaquim, A., Vilela, E., Capela, A., Costa, A. J., Duarte, B., Rato, N. D., Afreixo, V., Fontes Carvalho, R., Santos, M., & Ribeiro, F. (2024). Cost-effectiveness analysis of a cardio-oncology rehabilitation framework compared to an exercise intervention for cancer survivors with high cardiovascular risk. European journal of preventive cardiology, zwae181. Advance online publication. https://doi.org/10.1093/eurjpc/zwae181
9.	Retèl VP, van der Molen L, Steuten LM, van den Brekel MW, Hilgers FJ. A cost-effectiveness analysis of using TheraBite in a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy. Eur Arch Otorhinolaryngol. 2016 Mar;273(3):709-18. doi: 10.1007/s00405-015-3541-9.
10.	Retèl VP, van der Molen L, Hilgers FJ, Rasch CR, L'Ortye AA, Steuten LM, van Harten WH. A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy. BMC Cancer. 2011 Nov 3;11:475. doi: 10.1186/1471-2407-11-475.
11.	Jansen, F., Coupé, V. M. H., Eerenstein, S. E. J., Cnossen, I. C., van Uden-Kraan, C. F., de Bree, R., Doornaert, P., Halmos, G. B., Hardillo, J. A. U., van Hinte, G., Honings, J., Leemans, C. R., & Verdonck-de Leeuw, I. M. (2021). Cost-utility and cost-effectiveness of a guided self-help head and neck exercise program for patients treated with total laryngectomy: Results of a multi-center randomized controlled trial. Oral oncology, 117, 105306. https://doi.org/10.1016/j.oraloncology.2021.105306
12.	Edbrooke, L., Denehy, L., Patrick, C., & Tuffaha, H. (2021). Cost-effectiveness analysis of home-based rehabilitation compared to usual care for people with inoperable lung cancer. European journal of cancer care, 30(6), e13501. https://doi.org/10.1111/ecc.13501 .
Reason 3. Economic evaluation was not reported (S).	
13.	Rafn BS, Hung S, Hoens AM, McNeely ML, Singh CA, Kwan W, Dingee C, McKeivitt EC, Kuusk U, Pao J, Van Laeken N, Goldsmith CH, Campbell KL. Prospective surveillance and targeted physiotherapy for arm morbidity after

	breast cancer surgery: a pilot randomized controlled trial. Clin Rehabil. 2018 Jun;32(6):811-826. doi: 10.1177/0269215518757292.
14.	van de Wiel HJ, Stuiver MM, May AM, van Grinsven S, Aaronson NK, Oldenburg HSA, van der Poel HG, Koole SN, Retèl VP, van Harten WH, Groen WG. Effects of and Lessons Learned from an Internet-Based Physical Activity Support Program (with and without Physiotherapist Telephone Counselling) on Physical Activity Levels of Breast and Prostate Cancer Survivors: The PABLO Randomized Controlled Trial. Cancers (Basel). 2021 Jul 21;13(15):3665. doi: 10.3390/cancers13153665.